Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

Sponsor:

NRG

Sponsor Study ID:

NRG-GI008

CTO #:

104069

NCT Number:

NCT05174169

Phase:

II/III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Colon

Study Objectives:

To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. Time to positive event is defined as time from randomization to the first ctDNA postive result for the immediate arm (arm 1) and to the 2nd ctDNA positive result for the delated arm (arm 2) to allow for the potential effect of delayed adjuvant chemotherapy. Patients recurred without a positive ctDNA result will be considered to have ctDNA positive status at the time of recurrence for both study arms.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)